

Research Project

Preclinical in vivo proof of mechanism study of selective mTORC1 inhibitors

Third-party funded project

Project title Preclinical in vivo proof of mechanism study of selective mTORC1 inhibitors

Principal Investigator(s) [Hall, Michael N.](#) ; [Maier, Timm](#) ;

Organisation / Research unit

Departement Biozentrum / Structural Biology (Maier)

Departement Biozentrum / Biochemistry (Hall)

Department

Departement Biozentrum

Project start 01.07.2022

Probable end 30.06.2024

Status Active

Laufzeit 01.04.2022-31.01.2024

Increased activity of mammalian target of rapamycin complex 1(mTORC1) is linked to multiple disorders. We identified ten small compounds that selectively and efficiently inhibit mTORC1 in vitro with an innovative mode of action. We now aim to achieve preclinical proof of mechanism in mice.

Financed by

Innovation Promotion Agency CTI

Add publication

Add documents

Specify cooperation partners